References

• Archuleta, S., Chia, P. Y., Wei, Y., Syed-Omar, S. F., Low, J. G., Oh, H. M., . . . Kamarulzaman, A. (2019). Predictors and Clinical Outcomes of Poor Platelet Recovery in Adult Dengue With Thrombocytope-nia: A Multicenter, Prospective Study. Clinical Infectious Diseases, 71(2), 383-389. google scholar
• Assir, M. Z. K., & Ahmad, F. (2017). Prophylactic platelet transfusion does not reduce risk of clinical bleeding in adults with dengue and thrombocytopaenia. BMJ Evidence-Based Medicine, 22(6), 225. google scholar
• Boo, Y., Lim, S., P’ng, H., Liam, C., & Huan, N. (2019). Persistent thrombocytopenia following dengue fever: What should we do? Malaysian Family Physician: the Official Journal of the Academy of Family Physicians of Malaysia, 14(3), 71-73. google scholar
• Brinc, D., & Lazarus, A. H. (2009). Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. ASH Education Program Book, 2009(1), 185-191. google scholar
• Dimaano, E. M., Saito, M., Honda, S., Miranda, E. A., Alonzo, M. T., Valerio, M. D., . . . Oishi, K. (2007). Lack of efficacy of high-dose in-travenous immunoglobulin treatment of severe thrombocytope-nia in patients with secondary dengue virus infection. American Journal of Tropical Medicine and Hygiene, 77(6), 1135-1138. google scholar
• Dorner, A. J., Goldman, S. J., & Keith, J. C. (1997). Interleukin-11. BioDrugs, 8(6), 418-429. google scholar
• FDA (Aug 26, 2014). PROMACTA® (eltrombopag). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/207027s003lbl.pdf google scholar
• US. FDA (2008). Highlight of prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/ label/2008/125268lbl.pdf google scholar
• National Institutes of Health. (2017). LiverTox: clinical and re-search information on drug-induced liver injury. Nih. gov https:// livertox. nih. gov. google scholar
• Hosangadi, D. (2019). The global rise of dengue infections. Retrieved from https://www.outbreakobservatory.org/out-breakthursday-1/3/21/2019/the-global-rise-of-dengue-infections?rq=dengue google scholar
• Humbrecht, C., Kientz, D., & Gachet, C. (2018). Platelet transfusion: Current challenges. Transfusion Clinique et Biologique, 25(3), 151164. doi:10.1016/j.tracli.2018.06.004 google scholar
• Izak, M., & Bussel, J. B. (2014). Management of thrombocytopenia. F1000 Prime Reports, 6, 45. google scholar
• Jolles, S., Sewell, W., & Misbah, S.A. (2005). Clinical uses of intravenous immunoglobulin. Clinical and Experimental Immunology, 142(1), 1. google scholar
• Kalayanarooj, S. (2011). Clinical manifestations and management of dengue/DHF/DSS. Tropical Medicine and Health, 11120801931112080193. google scholar
• Kharya, G., Yadav, S. P., Katewa, S., & Sachdeva, A. (2011). Manage-ment of severe refractory thrombocytopenia in dengue hemor-rhagic fever with intravenous anti-D immune globulin. Pediatric Hematology and Oncology, 28(8), 727-732. google scholar
• Kohli, U., Saharan, S., Lodha, R., & Kabra, S. (2008). Persistent thrombocytopenia following dengue shock syndrome. The In-dian Journal of Pediatrics, 75(1), 82-83. google scholar
• Kularatne, S. (2005). Survey on the management of dengue infec-tion in Sri Lanka: opinions of physicians and pediatricians. South-east Asian Journal of Tropical Medicine and Public Health, 36(5), 1198. Kularatne, S., Walathara, C., Mahindawansa, S., Wijesinghe, S., Pathirage, M., Kumarasiri, P., & Dissanayake, A. (2009). Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study. Postgraduate Medi-cal Journal, 85(1008), 525-529. google scholar
• Kumar, P., Charaniya, R., Ghosh, A., & Sahoo, R. (2016). Intravenous immunoglobulin responsive persistent thrombocytopenia after dengue Haemorrhagic fever. Journal of Clinical and Diagnostic Research, 10(4), 10. google scholar
• Kumar, V., Gupta, K., Soneja, M., & Biswas, A. (2018). Intravenous immunoglobulin for severe thrombocytopenia in secondary dengue. Case Reports, 2018, bcr-2018. google scholar
• Lazarus, A. H., Freedman, J., & Semple, J. (1998). Intravenous immu-noglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfusion Science, 19(3), 289-294. google scholar
• Lee, T. H., Wong, J. G., Leo, Y. S., Thein, T. L. (2016). Potential harm of prophylactic platelet transfusion in adult dengue patients. Plos Neglected Tropical Diseases, 10(3), 4576. google scholar
• Leong, K., & Srinivas, P. (1993). Corticosteroid-responsive pro-longed thrombocytopenia following dengue haemorrhagic fe-ver. Medical Journal of Malaysia, 48, 369-369. google scholar
• Lye, D. C., Lee, V. J., Sun, Y., & Leo, Y. S. (2009). Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clinical Infec-tious Diseases, 48(9), 1262-1265. google scholar
• Medin, C. L., & Rothman, A. L. (2006). Cell type-specific mecha-nisms of interleukin-8 induction by dengue virus and differential response to drug treatment. The Journal of Infectious Diseases, 193(8), 1070-1077. google scholar
• Medscape. (2020). oprelvekin (Rx). Retrieved from https://refer-ence.medscape.com/drug/neumega-interleukin-11-oprelve-kin-342165#10 google scholar
• Min, M., Aye, M., Shwe, T., & Swe, T. (1975). Hydrocortisone in the management of dengue shock syndrome. The Southeast Asian Journal of Tropical Medicine and Public Health, 6(4), 573-579. google scholar
• Monath, T. P. (2007). Dengue and yellow fever—challenges for the development and use of vaccines. New England Journal of Medicine, 357(22), 2222-2225. google scholar
• NHLBI. (2020). Thrombocytopenia. Retrieved from https://www. nhlbi.nih.gov/health-topics/thrombocytopenia google scholar
• Nisar, S., Shaban, M., & Shah, S. (2018). Role of Recombinant Hu-man Interleukin-11 in Thrombocytopenia Associated with Den-gue Fever. International Journal of Advanced Biotechnology and Research, 9(1), 1985-1988. google scholar
• World Health Organization, Special Programme for Research, Train-ing in Tropical Diseases, World Health Organization. Department of Control of Neglected Tropical Diseases, World Health Organization. Epidemic, & Pandemic Alert. (2009). Dengue: guidelines for diagno-sis, treatment, prevention and control. World Health Organization. google scholar
• Pannu, A. K., Bhalla, A., Singhal, M., Suri, V., Shafiq, N., & Varma, S. (2017). Safety and efficacy of a single dose of anti-D (WinRho®) in severe thrombocytopenia secondary to dengue virus infection. Indian Journal of Critical Care Medicine, 21(2), 80. google scholar
• Perez Ruixo, J. J., Green, B., Doshi, S., Wang, Y. M., & Mould, D. R. (2012). Romiplostim dose response in patients with immune thrombocytopenia. The Journal of Clinical Pharmacology, 52(10), 1540-1551. google scholar
• Pesaro, A. E., D’Amico, E., & Aranha, L. F. C. (2007). Dengue: car-diac manifestations and implications in antithrombotic treat-ment. Scielo Brazil, 89(2), 12-15. https://doi.org/10.1590/S0066-782X2007001400015 google scholar
• Pongpanich, B., Bhanchet, P., Phanichyakarn, P., & Valyasevi, A. (1973). Studies on dengue hemorrhagic fever. Clinical study: an evaluation of steroids as a treatment. Journal of the Medical As-sociation of Thailand, 56(1), 6-14. google scholar
• Pothapregada, S., Kamalakannan, B., & Thulasingam, M. (2015). Role of platelet transfusion in children with bleeding in dengue fever. Journal of Vector Borne Diseases, 52(4), 304-308. google scholar
• Rajapakse, S., de Silva, N. L., Weeratunga, P., Rodrigo, C., & Fer-nando, S. D. (2017). Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review. Transactions of The Royal Society of Tropical Medicine and Hygiene, 111(10), 433-439. doi:10.1093/trstmh/trx079 google scholar
• Recht, M. (2009). Thrombocytopenia and anemia in infants and children. Emergency Medicine Clinics of North America, 27(3), 505523. google scholar
• Rodriguez-Mejorada, M. S., Rosel-Gomez, G. C., Rosado-Castro, R. A., & Ruiz-Argüelles, G. J. (2010). Refractory thrombocytopenia as-sociated with dengue hemorrhagic fever responds to romiplos-tim. Blood, 116 (21), 4668. google scholar
• Roy, S. (2019). Thrombopoietin Receptor Agonists: Can These Be the Future Answer to the Deadly Thrombocytopenia in Dengue Fever? Cureus, 11(4). google scholar
• Ruberto, I., Marques, E., Burke, D. S., & Van Panhuis, W. G. (2015). The availability and consistency of dengue surveillance data pro-vided online by the World Health Organization. Plos Neglected Tropical Diseases, 9(4): e0003511. https://doi.org/10.1371/journal. pntd.0003511 google scholar
• Sajib Chakraborty, A. K. (2019, 15 June 2020). Efficacy and Safety of Eltrombopag to correct thrombocytopenia in moderate to severe dengue patients- a Phase II Randomized Controlled Clinical Trial. Retrieved from https://www.cochranelibrary.com/central/ doi/10.1002/central/CN-02071746/full?highlightAbstract=deng u%7Celtrombopag%7Cdengue google scholar
• Soff, G. A., Miao, Y., Bendheim, G., Batista, J., Mones, J. V. (2019). Romiplostim treatment of chemotherapy-induced thrombocyto-penia. Journal of Clinical Oncology, 37(31), 2892-2898. google scholar
• Soumya, M. H., Das, S., & Kalyani, R. (2019). Platelet Transfusion Practice in Dengue Epidemic; Current Trends and Challenges-an Institutional Study. Journal of Blood & Lymph, 9(4), 255 google scholar
• Sridharan, A., Chen, Q., Tang, K. F., Ooi, E. E., Hibberd, M. L., & Chen, J. (2013). Inhibition of megakaryocyte development in the bone marrow underlies dengue virus-induced thrombocytopenia in humanized mice. Journal of Virology, 87(21), 11648-11658. google scholar
• Subbiah, A., Mahajan, S., Yadav, R. K., & Agarwal, S. K. (2018). Intra-venous immunoglobulin therapy for dengue capillary leak syn-drome in a renal allograft recipient. British Medical Journal. Case Reports, 225225. doi.org/10.1136/bcr-2018-225225 google scholar
• Suliman, M. I., Qayum, I., & Saeed, F. (2014). Randomized clinical trial of human interleukin-11 in dengue fever-associated throm-bocytopenia. Journal of College of Physicians and Surgeons Pakistan, 24(3), 164-168. google scholar
• Sumarmo, D., Talogo, W., Asrin, A., Isnuhandojo, B., & Sahudi, A. (1982). Failure of hydrocortisone to affect outcome in dengue shock syndrome. Pediatrics, 69(1), 45-49. google scholar
• Tam, D. T., Ngoc, T. V., Tien, N. T., Kieu, N. T., Thuy, T. T., Thanh, L. T., . . . Wills, B. A. (2012). Effects of short-course oral corticoste-roid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clinical Infectious Diseases, 55(9), 1216-1224. doi:10.1093/cid/cis655 google scholar
• Tassniyom, S., Vasanawathana, S., Chirawatkul, A., & Rojanasuphot, S. (1993). Failure of high-dose methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind study. Pediatrics, 92(1), 111-115. google scholar
• Verma, S. P., Hamide, A., Wadhwa, J., & Sivamani, K. (2013). Corti-costeroid responsive prolonged thrombocytopenia in a case of dengue fever. British Medical Journal. Case Reports, 2013. google scholar
• Vishnu, P., & Aboulafia, D. M. (2016). Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. Journal of Blood Medicine, 7, 99-106. https://doi.org/10.2147/JBM. S80646 google scholar
• WHO. (2019). Outbreak update - Dengue in Pakistan, 1 Decem-ber 2019. Epidemic and pandemic-prone diseases. Retrieved from http://www.emro.who.int/pandemic-epidemic-diseases/den-gue/outbreak-update-dengue-in-pakistan-1-december-2019. html google scholar
• Widya, M., & Martoatmodjo, K. (1975). Clinical observations on dengue shock syndrome. An evaluation of steroid treatment. Paediatrica Indonesiana, 15(5/6), 151-160. google scholar
• Shailendra, D. T., Ngoc, T. V., Tien, N. T., Kieu, N. T., Thuy, T. T., Thanh, L. T., . . . Wills, B. A. (2012). Effects of short-course oral corticoste-roid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clinical Infectious Diseases, 55(9), 1216-1224. doi:10.1093/cid/cis655 google scholar

Citations